O.V. KHEGAY, N.V. SELYANINA

Perm State Medical University, Perm

 Contact:

Khegay O.V. ― graduate student of the Department of Neurology named after V.P. Pervushin

Address: 15G Chernyshevskogo St., apt. 36, Perm, Russian Federation, 614002, tel. +7-909-106-55-02, e-mail: gamletslemon@yandex.ru

Objective ― to study the effect of the neuropeptide galanin on the motor manifestations of Parkinson’s disease.

Material and methods. During the work, the case-control study design was used. 73 patients (40 women and 33 men) with an established diagnosis of Parkinson’s disease (PD) without a burdened somatic history took part therein. As a control group, 16 practical healthy individuals were examined, comparable in gender and age to the main group. The Hoehn and Yahr scale of motor disorders in case of Parkinson’s disease and the unified scale for assessing manifestations of Parkinson’s disease were used for the study. The quantitative content of the neuropeptide galanin was carried out by ELISA. Data processing was carried out using the software package Statistica 10.0 with nonparametric methods.

Results. In patients with PD, a decrease in serum galanin was noted. An inverse relationship was found between the level of serum galanin and the number of points on the unified scale for assessing manifestations of Parkinson’s disease, reflecting the severity of motor manifestations of Parkinson’s disease, as well as the severity of the disease on the Hoehn and Yahr scale.

Conclusion. Decreased serum galanine level is associated with more severe motor impairment in case of PD.

Key words: Parkinson’s disease, motor manifestations, galanin. 

(For citation: Khegay O.V., Selyanina N.V. Effect of the neuropeptide galanin on the motor manifestations of Parkinson’s disease. Practical medicine. 2019. Vol. 17, № 7, P. 134-137)

REFERENCES

1. Levin O.S., Fedorova N.V. Bolezn’ Parkinsona [Parkinson’s disease]. Moscow: MEDpress-inform, 2016. P. 8.
2. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. European Journal of Epidemiology, 2011, Jun, no. 26, rr. 1-58.
3. Olanow C.W., Schapira A.H.V. Therapeutic prospects for Parkinson disease. Annals of Neurology, 2013, no. 74 (3), rr. 337-347.
4. Inoue K., Tsuda M., Koizumi S. Chronic pain and microglia: the role of ATP. Novartis Found Symp, 2004, no. 261, rr. 55-64.
5. Servetskiy K.L. Rol’ neyropeptida galanina v regulyatsii pamyati, obucheniya i v patogeneze parkinsonicheskogo i epilepticheskogo sindromov (eksperimental’noe issledovanie): avtoref. dis. … kand. med. nauk [The role of the galanin neuropeptide in the regulation of memory, learning, and in the pathogenesis of parkinsonian and epileptic syndromes (experimental study). Synopsis of dis. PhD med. sciences], 1994. 18 p.